MCID: SRC014
MIFTS: 68

Sarcoma

Categories: Cancer diseases, Bone diseases

Aliases & Classifications for Sarcoma

MalaCards integrated aliases for Sarcoma:

Name: Sarcoma 12 29 55 6 15 73
Connective and Soft Tissue Neoplasm 12
Tumor of Soft Tissue and Skeleton 12
Sarcoma - Category 73

Classifications:



External Ids:

Disease Ontology 12 DOID:1115
ICD10 33 C49
ICD9CM 35 171 171.9
SNOMED-CT 68 187985009 93765001

Summaries for Sarcoma

Disease Ontology : 12 A cell type cancer that has material basis in abnormally proliferating cells derives from embryonic mesoderm.

MalaCards based summary : Sarcoma, also known as connective and soft tissue neoplasm, is related to sarcoma, synovial and undifferentiated pleomorphic sarcoma. An important gene associated with Sarcoma is BACH1-IT2 (BACH1 Intronic Transcript 2
Ten lncRNAs, including RP11-560J1.2, AP001432.14, RP4-665J23.1, LINC00680, AC006129.2, RP11-230G5.2, BACH1-IT2, RP11-274B21.9, RP11-504A18.1 and RP11-713P17.3, were selected to calculate a risk score. The risk score could effectively predict patients' outcome, such as the status of mitotic count of tumor cells, person neoplasm cancer and residual tumor. More inspiringly, the risk score generated from the 10-lncRNA signature was an independent prognostic indicator for soft-tissue sarcoma patients.
Dysfunction Pattern: Association), and among its related pathways/superpathways are GPCR Pathway and Developmental Biology. The drugs Doxil and Fusilev have been mentioned in the context of this disorder. Affiliated tissues include bone, myeloid and lung, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 A sarcoma is a cancer that arises from transformed cells of mesenchymal origin. Thus, malignant tumors... more...

Related Diseases for Sarcoma

Diseases related to Sarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 995)
# Related Disease Score Top Affiliating Genes
1 sarcoma, synovial 34.9 KIT SSX1 SSX2
2 undifferentiated pleomorphic sarcoma 34.6 KIT KRAS PIK3CA
3 spindle cell synovial sarcoma 34.4 KIT SSX1 SSX2
4 ewing sarcoma 34.2 EWSR1 FLI1 JUN KIT TP53
5 uterine carcinosarcoma 33.3 HRAS KIT PIK3CA TP53
6 malignant mesenchymoma 33.1 EWSR1 KIT TP53
7 gastrointestinal stromal tumor 32.9 BRAF HOTAIR KIT KRAS TP53
8 muscle cancer 32.7 EWSR1 KIT TP53
9 liver angiosarcoma 32.5 HRAS KRAS TP53
10 ewing's family of tumors 32.0 EWSR1 FLI1 KIT RB1
11 histiocytoma 31.6 EWSR1 KIT TP53
12 angiosarcoma 31.3 FLI1 KIT KRAS
13 cystadenocarcinoma 30.7 HRAS PIK3CA TP53
14 breast cancer 30.6 BRAF HOTAIR HRAS JUN KIT KRAS
15 pulmonic stenosis 30.5 BRAF HRAS KRAS
16 connective tissue cancer 30.5 EWSR1 KIT SSX1 TP53
17 spitz nevus 30.5 BRAF HRAS TP53
18 leukemia, acute myeloid 30.4 HOTAIR HRAS JUN KIT KRAS TP53
19 mature teratoma 30.4 BRAF KRAS TP53
20 lung benign neoplasm 30.4 HRAS KRAS TP53
21 adenocarcinoma 30.4 BRAF HRAS KIT KRAS PIK3CA RB1
22 leukemia, chronic lymphocytic 30.2 BRAF HRAS KRAS LYN TP53
23 skin melanoma 30.2 BRAF HRAS KIT PIK3CA TP53
24 lung adenoid cystic carcinoma 30.2 HRAS KIT KRAS PIK3CA
25 testicular germ cell tumor 30.1 BRAF KIT TP53
26 adenoid cystic carcinoma 29.9 HRAS KIT KRAS PIK3CA TP53
27 leukemia, chronic myeloid 29.9 HOTAIR HRAS KIT LYN SRC
28 cholangiocarcinoma 29.8 HRAS KIT KRAS PIK3CA TP53
29 small cell cancer of the lung 29.7 HOTAIR KIT PIK3CA RB1 TP53
30 neuroblastoma 29.7 HOTAIR KIT LYN PIK3CA TP53
31 myeloma, multiple 29.6 BRAF HOTAIR HRAS JUN KRAS TP53
32 adrenocortical carcinoma, hereditary 29.6 BRAF PIK3CA TP53
33 glioblastoma 29.5 BRAF HOTAIR HRAS PIK3CA RB1 TP53
34 lung cancer susceptibility 3 29.5 BRAF HOTAIR HRAS KRAS PIK3CA TP53
35 squamous cell carcinoma 29.5 BRAF HOTAIR HRAS KRAS PIK3CA RB1
36 cervical cancer 29.4 HOTAIR HRAS PIK3CA RB1 TP53
37 nasopharyngeal carcinoma 29.4 HOTAIR HRAS JUN PIK3CA TP53
38 bladder cancer 29.3 HOTAIR HRAS KRAS RB1 SRC TP53
39 thyroid cancer 29.3 BRAF HOTAIR HRAS KRAS PIK3CA TP53
40 ovarian cancer 28.9 BRAF HOTAIR JUN KRAS PIK3CA TP53
41 prostate cancer 28.6 HOTAIR HRAS JUN KRAS PIK3CA RB1
42 lung cancer 28.4 BRAF HOTAIR HRAS JUN KIT KRAS
43 hepatocellular carcinoma 28.4 HOTAIR HRAS JUN KRAS PIK3CA RB1
44 kaposi sarcoma 12.6
45 myeloid sarcoma 12.4
46 follicular dendritic cell sarcoma 12.3
47 alveolar soft part sarcoma 12.3
48 endometrial stromal sarcoma 12.3
49 soft tissue sarcoma 12.3
50 epithelioid sarcoma 12.3

Graphical network of the top 20 diseases related to Sarcoma:



Diseases related to Sarcoma

Symptoms & Phenotypes for Sarcoma

GenomeRNAi Phenotypes related to Sarcoma according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.65 PIK3CA KRAS HRAS BRAF
2 Decreased viability GR00106-A-0 10.65 KRAS
3 Decreased viability GR00221-A-1 10.65 PIK3CA KRAS HRAS KIT
4 Decreased viability GR00221-A-2 10.65 PIK3CA YES1 KRAS HRAS JUN
5 Decreased viability GR00221-A-3 10.65 YES1 HRAS JUN
6 Decreased viability GR00221-A-4 10.65 PIK3CA YES1 BRAF
7 Decreased viability GR00301-A 10.65 SRC KRAS KIT BRAF
8 Decreased viability GR00381-A-1 10.65 KRAS BRAF
9 Decreased viability GR00402-S-2 10.65 PIK3CA SRC YES1 KRAS HRAS JUN
10 Decreased cell migration GR00055-A-1 9.87 YES1 LYN PIK3CA FES HRAS BRAF
11 Decreased substrate adherent cell growth GR00193-A-1 9.86 KIT
12 Decreased substrate adherent cell growth GR00193-A-2 9.86 YES1 KIT
13 Decreased substrate adherent cell growth GR00193-A-3 9.86 YES1 BRAF
14 Decreased substrate adherent cell growth GR00193-A-4 9.86 YES1 BRAF KIT
15 Decreased viability in HMC1.1 cells GR00105-A-0 9.13 SRC LYN KIT
16 Increased cell migration GR00055-A-3 9.02 LYN PIK3CA HRAS BRAF KRAS

MGI Mouse Phenotypes related to Sarcoma:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.34 JUN HRAS KIT RB1 PIK3CA KRAS
2 endocrine/exocrine gland MP:0005379 10.31 KRAS KIT JUN PIK3CA SRC RB1
3 immune system MP:0005387 10.31 KRAS KIT JUN PIK3CA SRC RB1
4 mortality/aging MP:0010768 10.31 JUN HRAS KIT LYN RB1 PIK3CA
5 cardiovascular system MP:0005385 10.3 JUN HRAS KIT RB1 PIK3CA KRAS
6 integument MP:0010771 10.3 KRAS KIT JUN PIK3CA SRC RB1
7 hematopoietic system MP:0005397 10.29 JUN KIT LYN RB1 KRAS TP53
8 nervous system MP:0003631 10.25 KRAS KIT JUN PIK3CA SRC RB1
9 embryo MP:0005380 10.23 JUN KRAS KIT PIK3CA RB1 TP53
10 craniofacial MP:0005382 10.19 KRAS KIT SRC RB1 TP53 HRAS
11 digestive/alimentary MP:0005381 10.19 KRAS KIT RB1 LYN TP53 BRAF
12 liver/biliary system MP:0005370 10.16 KRAS KIT JUN RB1 LYN TP53
13 neoplasm MP:0002006 10.16 KRAS KIT PIK3CA SRC RB1 TP53
14 muscle MP:0005369 10.08 KRAS KIT RB1 PIK3CA TP53 FLI1
15 normal MP:0002873 10.02 JUN KRAS KIT RB1 TP53 YES1
16 no phenotypic analysis MP:0003012 9.95 KIT JUN HRAS RB1 PIK3CA KRAS
17 renal/urinary system MP:0005367 9.86 KRAS KIT RB1 LYN TP53 YES1
18 respiratory system MP:0005388 9.85 KRAS KIT JUN SRC RB1 LYN
19 pigmentation MP:0001186 9.8 KRAS KIT SRC RB1 TP53 BRAF
20 skeleton MP:0005390 9.65 JUN KRAS KIT PIK3CA RB1 TP53
21 vision/eye MP:0005391 9.28 KRAS KIT JUN PIK3CA RB1 TP53

Drugs & Therapeutics for Sarcoma

FDA approved drugs:

# Drug Name Active Ingredient(s) 18 Company Approval Date
1
Doxil 18 49 DOXORUBICIN HYDROCHLORIDE Alza June 1999
2
Fusilev 18 LEVOLEUCOVORIN CALCIUM Spectrum Pharmaceuticals March of 2008
3
Intron A 18 49 INTERFERON ALFA-2B Schering-Plough December 1997/ December 1995/ March 1997
4
Taxol 18 49 PACLITAXEL Bristol-Myers Squibb August 1997
5
Votrient 18 49 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline April 2012/ October of 2009

Drugs for Sarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 609)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
2
Doxorubicin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
3
Bleomycin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 11056-06-7 5360373
4
Vincristine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 2068-78-2, 57-22-7 5978
5
Efavirenz Approved, Investigational Phase 4,Phase 3,Not Applicable 154598-52-4 64139
6
Ritonavir Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 155213-67-5 392622
7
Oxaliplatin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 61825-94-3 5310940 9887054 43805 6857599
8
Lamivudine Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 134678-17-4 60825
9
Nevirapine Approved Phase 4,Phase 3 129618-40-2 4463
10
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
11
Emtricitabine Approved, Investigational Phase 4,Phase 3,Not Applicable 143491-57-0 60877
12
Lopinavir Approved Phase 4,Phase 2,Phase 3 192725-17-0 92727
13
Bevacizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 216974-75-3
14
Capecitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 154361-50-9 60953
15
Aspirin Approved, Vet_approved Phase 4,Phase 2,Not Applicable 50-78-2 2244
16
Dalteparin Approved Phase 4,Phase 1,Not Applicable 9005-49-6
17
Enoxaparin Approved Phase 4,Not Applicable 9005-49-6 772
18
Heparin Approved, Investigational Phase 4,Phase 1,Not Applicable 9005-49-6 772 46507594
19
Ethiodized oil Approved, Investigational Phase 4 8008-53-5
20
Doxil Approved June 1999 Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 31703
21 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
23 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
25 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
26 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
27 Topoisomerase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
28 Vaccines Phase 4,Phase 3,Phase 1,Phase 2
29 Anti-HIV Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
30 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
31 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
32 Anti-Retroviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
33 Antiviral Agents Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1
34 Nucleic Acid Synthesis Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
35 HIV Protease Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
36
protease inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
37 Angiogenesis Inhibitors Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
38 Angiogenesis Modulating Agents Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable,Early Phase 1
39 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
40 Antibodies Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
41 Antibodies, Monoclonal Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
42 Immunoglobulins Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1,Not Applicable
43 Pharmaceutical Solutions Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
44 Analgesics Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
45 Analgesics, Non-Narcotic Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
46 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
47 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
48 Cyclooxygenase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
50 Cytochrome P-450 CYP3A Inducers Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable

Interventional clinical trials:

(show top 50) (show all 1793)
# Name Status NCT ID Phase Drugs
1 EpSSG (European Soft Tissue Sarcoma Study Group) Protocol for Non-Metastatic Rhabdomyosarcoma in Children Unknown status NCT00339118 Phase 4 doxorubicin, cytoxan
2 Optimizing Influenza Vaccination in Surgical Oncology Patients Unknown status NCT01698177 Phase 4
3 Stereotactic Body Radiotherapy for Head and Neck Tumors Unknown status NCT01344356 Phase 4
4 HIV/AIDS Kaposis Sarcoma: Comparison of Response to HAART vs HAART Plus CXT Completed NCT00380770 Phase 4 Generic HAART Triomune : d4T, 3TC, NVP;Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV
5 Anti-Retrovirals for Kaposi's Sarcoma Completed NCT00444379 Phase 4 Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir
6 OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum. Completed NCT00577031 Phase 4 bevacizumab [Avastin];Oxaliplatin;Xeloda
7 Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT) Completed NCT00552240 Phase 4 tenofovir DF 300 mg QD;tenofovir DF 300 mg QD;emtricitabine 200 mg QD;emtricitabine 200 mg QD;Nevirapine 200 mg BID;Atazanavir 300 mg;Ritonavir 100 mg
8 Evaluation of Hyperbaric Oxygen Therapy on Wound Healing Following Management of Soft Tissue Sarcoma With Neo-Adjuvant Radiation and Surgical Resection Recruiting NCT03144206 Phase 4 Hyperbaric oxygen
9 Pharmacologic Interaction Between Ifosfamide and Aprepitant in Treated Patients With Soft Tissue Sarcoma Recruiting NCT03514381 Phase 4 Patients starting a treatment with Doxorubicin and Ifosfamide
10 Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer Recruiting NCT02301962 Phase 4 Panitumumab
11 Clinical Trial of Lithium Carbonate Combined With Neo-adjuvant Chemotherapy to Treat Osteosarcoma Recruiting NCT01669369 Phase 4 Lithium Carbonate;Placebo
12 Evaluation of Lipiodol® Ultra Fluid in Association With Surgical Glues During Vascular Embolization. Recruiting NCT02625389 Phase 4 Lipiodol® Ultra Fluid with surgical glues
13 Low Molecular Weight Heparin (LMWH) vs Aspirin for Venous Thromboembolism (VTE) Prophylaxis in Orthopaedic Oncology Enrolling by invitation NCT03244020 Phase 4 Aspirin 325mg;Enoxaparin 40Mg/0.4mL Prefilled Syringe
14 The Addition of Polychemotherapy to Adjuvant Radiotherapy in the Treatment of Non-Metastatic Uterine Sarcomas Unknown status NCT00162721 Phase 3 doxorubicin, ifosfamide, cisplatin
15 Combination Chemotherapy Plus Surgery and Radiation Therapy in Treating Patients With Ewing's Sarcoma Unknown status NCT00002516 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;mesna;vincristine sulfate
16 Trial Comparing Trabectedin to the Best Supportive Care in Patients With Sarcoma Unknown status NCT02672527 Phase 3 Trabectedin;Dexamethasone
17 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
18 Combination Chemotherapy With or Without Peripheral Stem Cell Transplantation, Radiation Therapy, and/or Surgery in Treating Patients With Ewing's Sarcoma Unknown status NCT00020566 Phase 3 busulfan;doxorubicin hydrochloride;etoposide;ifosfamide;melphalan;vincristine sulfate
19 A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma Unknown status NCT00002318 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate;Doxorubicin hydrochloride
20 Combination Chemotherapy in Treating Young Patients With Nonmetastatic Rhabdomyosarcoma Unknown status NCT00379457 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;topotecan hydrochloride;vincristine sulfate;vinorelbine tartrate
21 I-MVAC +/- Panitumumab as First-line Treatment of Advanced Urothelial Carcinoma Without H-Ras Nor K-Ras Mutations Unknown status NCT02818725 Phase 3 Chemotherapy;panitumumab
22 TB-IRIS NSAID Cox-2 Inhibitor Prevention Trial Unknown status NCT02060006 Phase 3 Meloxicam 7.5mg daily for 8 weeks
23 Hyperbaric Oxygen Therapy in Treating Long-Term Gastrointestinal Adverse Effects Caused by Radiation Therapy in Patients With Pelvic Cancer Unknown status NCT01087268 Phase 3
24 Imatinib Mesylate in Treating Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumor Unknown status NCT00685828 Phase 3 imatinib mesylate
25 A Clinical Trial on Efficacy and Safety for Lobaplatin and Gemcitabine in Combination With Docetaxel in the Second-line Treatments on Advanced Osteosarcoma Unknown status NCT02099396 Phase 2, Phase 3 Docetaxel+lobaplatin;Gemcitabine+lobaplatin
26 Evaluation of Zoledronic Acid as a Single Agent or as an Adjuvant to Chemotherapy in High Grade Osteosarcoma Unknown status NCT00691236 Phase 2, Phase 3 Zoledronic acid;Standard chemotherapy
27 A Trial of TH-302 in Combination With Doxorubicin Versus Doxorubicin Alone to Treat Patients With Locally Advanced Unresectable or Metastatic Soft Tissue Sarcoma Completed NCT01440088 Phase 3 TH-302 in Combination with Doxorubicin;Doxorubicin
28 A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma Completed NCT00131898 Phase 3
29 Comparison of Gemcitabine v. Gemcitabine Plus Docetaxel in Unresectable Soft Tissue Sarcoma Completed NCT00142571 Phase 3 Gemcitabine;Docetaxel
30 Comparison of Combination Chemotherapy Regimens in Treating Patients With Ewing's Sarcoma or Neuroectodermal Tumor Completed NCT00006734 Phase 3 cyclophosphamide;doxorubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
31 Doxorubicin in Treating Patients With AIDS-Related Kaposi's Sarcoma Completed NCT00002985 Phase 3 daunorubicin hydrochloride;pegylated liposomal doxorubicin hydrochloride
32 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
33 Phase 3 Study to Treat Patients With Soft Tissue Sarcomas Completed NCT02049905 Phase 3 Aldoxorubicin;Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)
34 Phase 3 Study to Compare the Efficacy and Safety of Eribulin With Dacarbazine in Subjects With Soft Tissue Sarcoma Completed NCT01327885 Phase 3 Eribulin mesylate 1.4 mg/m^2 intravenous;Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV
35 An Efficacy and Safety Study of Trabectedin Versus Doxorubicin-Based Chemotherapy in Participants With Translocation-Related Sarcomas (TRS) Completed NCT00796120 Phase 3 Trabectedin;Doxorubicin;Ifosfamide
36 Observation Versus Post-surgery Radiotherapy After Complete Exeresis in Soft Tissues Members Sarcoma Completed NCT00870701 Phase 3
37 Study of Palifosfamide-tris in Combination With Doxorubicin in Patients With Front-line Metastatic Soft Tissue Sarcoma Completed NCT01168791 Phase 3 doxorubicin in combination with palifosfamide-tris;doxorubicin in combination with placebo
38 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
39 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
40 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
41 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
42 A Pilot Study Of the Effects of Highly Active Antiretroviral Therapy on Kaposi's Sarcoma in Zimbabwe Completed NCT00834457 Phase 2, Phase 3 abacavir/3TC/zidovudine;abacavir /3TC plus ritonavir boosted lopinavir
43 Paclitaxel Compared With Doxorubicin in Treating Patients With Advanced AIDS-Related Kaposi's Sarcoma Completed NCT00003350 Phase 3 paclitaxel;pegylated liposomal doxorubicin hydrochloride
44 Ridaforolimus in Treatment of Sarcoma-SUCCEED (Sarcoma Multi-Center Clinical Evaluation of the Efficacy of Ridaforolimus)(8669-011 AM6) Completed NCT00538239 Phase 3 ridaforolimus;Placebo
45 A Study of DOX-SL in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002319 Phase 3 Doxorubicin hydrochloride (liposomal)
46 Use of Stealth Liposomal Doxorubicin HCl ( DOX-SL ) in the Treatment of Moderate to Severe AIDS-Related Kaposi's Sarcoma. Completed NCT00002147 Phase 3 Doxorubicin hydrochloride (liposomal)
47 Safety and Effectiveness of an Experimental Drug, IM862, in Treating Kaposi's Sarcoma in AIDS Patients Completed NCT00002445 Phase 3 IM862
48 A Randomized Study of the Effect of Adjuvant Chemotherapy With Doxorubicin and Ifosfamide With Mesna in the Treatment of High-Grade Adult Extremity Soft Tissue Sarcoma Completed NCT00001300 Phase 3 doxorubicin;ifosfamide;mesna
49 Randomized, Comparative Trial of DOX-SL (Stealth Liposomal Doxorubicin Hydrochloride) Versus Bleomycin and Vincristine in the Treatment of AIDS-Related Kaposi's Sarcoma Completed NCT00002105 Phase 3 Doxorubicin hydrochloride (liposomal);Bleomycin sulfate;Vincristine sulfate
50 A Study of AVE8062 in Advanced-stage Soft Tissue Sarcoma After Failure of Anthracycline and Ifosfamide Chemotherapies Completed NCT00699517 Phase 3 OMBRABULIN (AVE8062);Placebo

Search NIH Clinical Center for Sarcoma

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Sarcoma

Genetic tests related to Sarcoma:

# Genetic test Affiliating Genes
1 Sarcoma 29

Anatomical Context for Sarcoma

MalaCards organs/tissues related to Sarcoma:

41
Bone, Myeloid, Lung, Kidney, Liver, T Cells, Uterus

Publications for Sarcoma

Articles related to Sarcoma:

(show top 50) (show all 10749)
# Title Authors Year
1
NTRK Fusions Define a Novel Uterine Sarcoma Subtype With Features of Fibrosarcoma. ( 29553955 )
2018
2
EWS-FLI1 regulates a transcriptional program in cooperation with Foxq1 in mouse Ewing sarcoma. ( 29945296 )
2018
3
Surgical management of esophageal sarcoma: a multicenter European experience. ( 29444281 )
2018
4
Neoadjuvant and adjuvant strategies in retroperitoneal sarcoma. ( 29472043 )
2018
5
Robust diagnosis of Ewing sarcoma by immunohistochemical detection of super-enhancer-driven EWSR1-ETS targets. ( 29416716 )
2018
6
Kaposi Sarcoma in the Era of Rapamycin Remains a Therapeutic Challenge in Organ Transplant Recipients. ( 29527986 )
2018
7
Supersulfated low-molecular weight heparin synergizes with IGF1R/IR inhibitor to suppress synovial sarcoma growth and metastases. ( 29225052 )
2018
8
Can the risks associated with uterine sarcoma morcellation really be prevented? Overview of the role of uterine morcellation in 2018. ( 29879489 )
2018
9
Characterizing the potency and impact of carbon ion therapy in a primary mouse model of soft tissue sarcoma. ( 29437879 )
2018
10
The Role of Adjuvant Radiotherapy for a Case of Primary Breast Sarcoma: A Plan Comparison between Three Modern Techniques and a Review of the Literature. ( 29849658 )
2018
11
RTK-RAS pathway mutation is enriched in myeloid sarcoma. ( 29789584 )
2018
12
Primary mediastinal histiocytic sarcoma presenting as pleural effusion. ( 29756323 )
2018
13
Fine needle aspiration of alveolar soft part sarcoma in a child: Cytomorphological clues for the surgical pathologist. ( 29661735 )
2018
14
A Rare Case of Retroperitoneal Follicular Dendritic Cell Sarcoma Identified by 99mTc-HYNIC-TOC SPECT/CT. ( 29863574 )
2018
15
Individualized doxorubicin sensitivity testing of undifferentiated soft tissue sarcoma (USTS) in a patient-derived orthotopic xenograft (PDOX) model demonstrates large differences between patients. ( 29384032 )
2018
16
Hepatic endometrial stromal sarcoma. ( 29843927 )
2018
17
Analysis of the immune infiltrate in undifferentiated pleomorphic sarcoma of the extremity and trunk in response to radiotherapy: Rationale for combination neoadjuvant immune checkpoint inhibition and radiotherapy. ( 29308306 )
2018
18
The t(1;10)(p22;q24) TGFBR3/MGEA5 Translocation in Pleomorphic Hyalinizing Angiectatic Tumor (PHAT), Myxoinflammatory Fibroblastic Sarcoma (MIFS), and Hemosiderotic Fibrolipomatous Tumor (HFLT). ( 29979612 )
2018
19
Evolution of Kaposi sarcoma in the past 30A years in a tertiary hospital of the European Mediterranean basin. ( 29934954 )
2018
20
Planning for Bone Excision in Ewing Sarcoma: Post-Chemotherapy MRI More Accurate Than Pre-Chemotherapy MRI Assessment. ( 29298256 )
2018
21
MicroRNA-638 inhibits cell growth and tubule formation by suppressing VEGFA expression in human Ewing sarcoma cells. ( 29263143 )
2018
22
Hanging Undifferentiated Embryonal Sarcoma of the Liver in Adult: an Unusual Presentation of an Aggressive Tumor. ( 29779073 )
2018
23
RIG-I Detects Kaposi's Sarcoma-Associated Herpesvirus Transcripts in a RNA Polymerase III-Independent Manner. ( 29970461 )
2018
24
Mediastinal monophasic synovial sarcoma with pericardial extension causing hemodynamic instability. ( 29765618 )
2018
25
Simultaneous Brain and Lung Histiocytic Sarcoma Revealed on 18F-FDG PET/CT. ( 29189378 )
2018
26
Case of classic Kaposi sarcoma of the penis successfully treated with radiotherapy. ( 29341256 )
2018
27
Coexistent cutaneous myeloid sarcoma in a patient with invasive papillary carcinoma of thyroid - A rare presentation. ( 29855456 )
2018
28
Intramuscular Epithelioid Sarcoma Presenting as Extrinsic Flexor Tightness inA the Forearm. ( 29602652 )
2018
29
A remarkable response to pazopanib, despite recurrent liver toxicity, in a patient with a high grade endometrial stromal sarcoma, a case report. ( 29357824 )
2018
30
Treatment of Uterine Sarcoma with rAd-p53 (Gendicine) Followed by Chemotherapy: Clinical Study of TP53 Gene Therapy. ( 29281902 )
2018
31
SMARCA4-deficient undifferentiated uterine sarcoma (malignant rhabdoid tumor of the uterus): a clinicopathologic entity distinct from undifferentiated carcinoma. ( 29700418 )
2018
32
CORR InsightsAr: Does an Algorithmic Approach to Using Brachytherapy and External Beam Radiation Result in Good Function, Local Control Rates, and Low Morbidity in Patients With Extremity Soft Tissue Sarcoma? ( 29443851 )
2018
33
Establishment and proteomic characterization of a novel cell line, NCC-UPS2-C1, derived from a patient with undifferentiated pleomorphic sarcoma. ( 29359268 )
2018
34
Alveolar Soft Part Sarcoma Presenting as Hypervascular Adrenal Metastasis. ( 29398970 )
2018
35
Paraneoplastic Pemphigus as a First Manifestation of an Intra-Abdominal Follicular Dendritic Cell Sarcoma: Rare Case and Review of the Literature. ( 29928216 )
2018
36
Primary jejunal interdigitating dendritic cell sarcoma. ( 29414390 )
2018
37
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients With Refractory Metastatic Soft Tissue Sarcoma. ( 29895706 )
2018
38
PD-1 blockade with nivolumab in endemic Kaposi sarcoma. ( 29324995 )
2018
39
Activity of decitabine in pericardial myeloid sarcoma. ( 29779081 )
2018
40
Phase II Study of Gemcitabine Plus Sirolimus in Previously Treated Patients with Advanced Soft-Tissue Sarcoma: a Spanish Group for Research on Sarcomas (GEIS) Study. ( 29177953 )
2018
41
Clear cell sarcoma arising from paraspinal ligament of thoracic spine: Report of an unusual case. ( 29676368 )
2018
42
Radiation-related soft tissue sarcoma in a veterinary technician. ( 29398573 )
2018
43
Allograft Reconstruction of the Extensor Mechanism after Resection of Soft Tissue Sarcoma. ( 29951320 )
2018
44
Image Gallery: Paraneoplastic pemphigus and follicular dendritic cell sarcoma. ( 29441554 )
2018
45
Primary Low-Grade Fibromyxoid Sarcoma of Kidney-an Extremely Rare Entity. ( 29973762 )
2018
46
A Rare Case of Relapsed Pediatric Acute Promyelocytic Leukemia with Skin Involvement by Myeloid Sarcoma. ( 29650946 )
2018
47
Establishment and characterization of the NCC-SS1-C1 synovial sarcoma cell line. ( 29450702 )
2018
48
Role of Radiotherapy in Mucosal Kaposi Sarcoma. ( 29383006 )
2018
49
Intraoperative Electron Radiation Therapy inA Retroperitoneal Sarcoma. ( 29353660 )
2018
50
Pyogenic granuloma-like Kaposi's sarcoma on the first toe. ( 29446122 )
2018

Variations for Sarcoma

ClinVar genetic disease variations for Sarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh37 Chromosome 17, 7577538: 7577538
2 TP53 NM_000546.5(TP53): c.743G> A (p.Arg248Gln) single nucleotide variant Pathogenic/Likely pathogenic rs11540652 GRCh38 Chromosome 17, 7674220: 7674220
3 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh37 Chromosome 3, 178936091: 178936091
4 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 GRCh38 Chromosome 3, 179218303: 179218303
5 PIK3CA NM_006218.3(PIK3CA): c.1633G> A (p.Glu545Lys) single nucleotide variant Pathogenic/Likely pathogenic rs104886003 NCBI36 Chromosome 3, 180418785: 180418785

Expression for Sarcoma

Search GEO for disease gene expression data for Sarcoma.

Pathways for Sarcoma

Pathways related to Sarcoma according to GeneCards Suite gene sharing:

(show top 50) (show all 157)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 BRAF HRAS JUN KIT KRAS LYN
2
Show member pathways
13.63 BRAF FES HRAS JUN KIT KRAS
3
Show member pathways
13.58 HRAS KIT KRAS LYN PIK3CA SRC
4
Show member pathways
13.51 BRAF HRAS KIT KRAS LYN PIK3CA
5
Show member pathways
13.43 HRAS KRAS LYN PIK3CA SRC TP53
6
Show member pathways
13.21 BRAF HRAS KIT KRAS LYN SRC
7
Show member pathways
13.13 BRAF HRAS JUN KRAS SRC TP53
8
Show member pathways
13.1 HRAS KIT KRAS PIK3CA RB1 TP53
9
Show member pathways
13.05 HRAS JUN KRAS LYN SRC TP53
10
Show member pathways
13.05 BRAF HRAS JUN KRAS PIK3CA RB1
11
Show member pathways
13.05 BRAF HRAS JUN KIT KRAS LYN
12
Show member pathways
13.04 BRAF HRAS JUN KRAS PIK3CA SRC
13
Show member pathways
13.04 BRAF FES HRAS JUN KRAS PIK3CA
14
Show member pathways
13.03 BRAF HRAS JUN KRAS LYN PIK3CA
15
Show member pathways
13 BRAF HRAS JUN KRAS PIK3CA SRC
16
Show member pathways
12.99 HRAS JUN KRAS RB1 TP53
17
Show member pathways
12.98 BRAF HRAS KRAS LYN PIK3CA SRC
18 12.97 BRAF HRAS JUN KIT KRAS PIK3CA
19
Show member pathways
12.94 BRAF HRAS JUN KRAS LYN SRC
20
Show member pathways
12.91 HRAS JUN KRAS PIK3CA TP53
21
Show member pathways
12.91 BRAF HRAS JUN KRAS SRC
22 12.91 BRAF HRAS JUN KIT KRAS TP53
23
Show member pathways
12.9 BRAF FES HRAS JUN KRAS
24
Show member pathways
12.88 BRAF HRAS KIT KRAS PIK3CA SRC
25
Show member pathways
12.86 HRAS KIT KRAS LYN PIK3CA SRC
26
Show member pathways
12.86 BRAF HRAS JUN KRAS PIK3CA RB1
27
Show member pathways
12.86 BRAF HRAS JUN KIT KRAS PIK3CA
28
Show member pathways
12.84 BRAF HRAS JUN KRAS SRC
29
Show member pathways
12.84 BRAF HRAS JUN KRAS PIK3CA SRC
30
Show member pathways
12.84 BRAF HRAS JUN KIT KRAS PIK3CA
31
Show member pathways
12.82 BRAF HRAS JUN KRAS RB1 TP53
32
Show member pathways
12.79 HRAS JUN KRAS PIK3CA SRC
33 12.75 BRAF HRAS KRAS PIK3CA SRC
34
Show member pathways
12.74 FES HRAS KRAS PIK3CA SRC TP53
35
Show member pathways
12.74 HRAS JUN KRAS LYN PIK3CA SRC
36
Show member pathways
12.73 HRAS LYN PIK3CA SRC YES1
37
Show member pathways
12.7 BRAF HRAS KRAS PIK3CA SRC
38
Show member pathways
12.66 BRAF HRAS JUN KRAS PIK3CA
39
Show member pathways
12.64 BRAF HRAS KRAS PIK3CA TP53
40
Show member pathways
12.63 HRAS JUN KRAS PIK3CA SRC
41
Show member pathways
12.59 HRAS JUN KRAS PIK3CA SRC
42
Show member pathways
12.59 HRAS JUN KRAS PIK3CA TP53
43
Show member pathways
12.58 BRAF HRAS JUN KRAS LYN SRC
44 12.57 HRAS JUN KRAS PIK3CA RB1 TP53
45
Show member pathways
12.57 BRAF HRAS JUN KRAS PIK3CA SRC
46
Show member pathways
12.55 HRAS JUN KRAS PIK3CA SRC
47
Show member pathways
12.55 HRAS JUN KIT KRAS PIK3CA
48
Show member pathways
12.55 HRAS JUN KRAS LYN PIK3CA RB1
49
Show member pathways
12.54 BRAF HRAS JUN KRAS
50
Show member pathways
12.53 HRAS KRAS LYN SRC

GO Terms for Sarcoma

Cellular components related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 9.02 FES KRAS LYN SRC YES1

Biological processes related to Sarcoma according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.99 BRAF HRAS JUN KIT SRC
2 cell migration GO:0016477 9.96 FES PIK3CA SRC YES1
3 axon guidance GO:0007411 9.94 HRAS KRAS PIK3CA SRC
4 Fc-epsilon receptor signaling pathway GO:0038095 9.92 HRAS JUN KRAS LYN PIK3CA
5 Fc-gamma receptor signaling pathway involved in phagocytosis GO:0038096 9.91 LYN PIK3CA SRC YES1
6 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.91 HRAS KRAS LYN SRC
7 protein autophosphorylation GO:0046777 9.91 FES KIT LYN SRC YES1
8 peptidyl-tyrosine phosphorylation GO:0018108 9.89 FES KIT LYN SRC YES1
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.88 LYN SRC TP53 YES1
10 ephrin receptor signaling pathway GO:0048013 9.87 HRAS LYN SRC YES1
11 T cell costimulation GO:0031295 9.85 LYN PIK3CA SRC YES1
12 negative regulation of neuron apoptotic process GO:0043524 9.85 BRAF HRAS JUN KRAS PIK3CA
13 liver development GO:0001889 9.84 JUN KRAS PIK3CA
14 visual learning GO:0008542 9.8 BRAF KIT KRAS
15 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.8 FES KIT LYN SRC YES1
16 positive regulation of MAP kinase activity GO:0043406 9.78 HRAS KIT KRAS SRC
17 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.77 KIT LYN SRC
18 peptidyl-tyrosine autophosphorylation GO:0038083 9.73 FES LYN SRC YES1
19 leukocyte migration GO:0050900 9.73 HRAS KRAS LYN PIK3CA SRC YES1
20 negative regulation of telomerase activity GO:0051974 9.65 SRC TP53
21 regulation of vascular permeability GO:0043114 9.65 SRC YES1
22 regulation of mast cell degranulation GO:0043304 9.65 FES LYN
23 response to isolation stress GO:0035900 9.63 HRAS KRAS
24 myeloid progenitor cell differentiation GO:0002318 9.63 BRAF KIT
25 response to mineralocorticoid GO:0051385 9.62 KRAS SRC
26 ERBB2 signaling pathway GO:0038128 9.62 HRAS KRAS PIK3CA SRC
27 Ras protein signal transduction GO:0007265 9.55 HRAS JUN KRAS RB1 TP53
28 epidermal growth factor receptor signaling pathway GO:0007173 9.35 FES HRAS KRAS PIK3CA SRC
29 regulation of cell proliferation GO:0042127 9.17 BRAF FES JUN KIT LYN SRC
30 phosphorylation GO:0016310 10.12 BRAF FES KIT LYN PIK3CA SRC
31 protein phosphorylation GO:0006468 10.08 BRAF FES KIT LYN PIK3CA SRC
32 positive regulation of cell proliferation GO:0008284 10.06 HRAS JUN KIT KRAS LYN
33 negative regulation of cell proliferation GO:0008285 10.04 HRAS JUN LYN RB1 TP53
34 positive regulation of gene expression GO:0010628 10.03 BRAF HRAS KIT KRAS SRC TP53
35 cell differentiation GO:0030154 10.02 BRAF FES FLI1 KIT LYN RB1

Molecular functions related to Sarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ubiquitin protein ligase binding GO:0031625 9.8 JUN LYN RB1 SRC TP53
2 protein kinase activity GO:0004672 9.8 BRAF FES KIT LYN SRC YES1
3 kinase activity GO:0016301 9.8 BRAF FES KIT LYN PIK3CA SRC
4 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.63 KIT PIK3CA SRC
5 enzyme binding GO:0019899 9.63 JUN LYN RB1 SRC TP53 YES1
6 phosphoprotein binding GO:0051219 9.54 LYN RB1 SRC
7 obsolete signal transducer, downstream of receptor, with protein tyrosine kinase activity GO:0004716 9.48 KIT LYN
8 protein tyrosine kinase activity GO:0004713 9.35 FES KIT LYN SRC YES1
9 non-membrane spanning protein tyrosine kinase activity GO:0004715 8.92 FES LYN SRC YES1
10 ATP binding GO:0005524 10.03 BRAF FES KIT LYN PIK3CA SRC

Sources for Sarcoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....